Seminars in Hematology
Volume 44 , Pages S22-S26 , July 2007

German Experience With Bendamustine Treating Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphomas

  • Mathias J. Rummel

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mathias J. Rummel, MD, PhD, Leiter des Schwerpunktes Hämatologie, Universitätsklinik Giessen, Klinikstr. 36, 35385 Giessen, Germany.

References 

  1. Ruffert K, Jahn H, Syrbe G, et al. Bendamustin as an alternative approach to treat malignant non-Hodgkin’s lymphoma. Z Klin Med. 1989;8:671–674
  2. Kath R, Blumenstengel K, Fricke HJ, Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2001;127:48–54
  3. Herold M, Keinert K, Anger G. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin’s disease. Onkologie. 1992;15:501–505
  4. Rummel MJ, Al Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–3389
  5. Friedberg JW, Cohen P, Cheson BD, et al. Bendamustine HCl (TREANDA) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-cell non-Hodgkin’s lymphoma (NHL): Results from a phase II multicenter single-agent study (SDX-105-01). Blood. 2005;106:70a;(abstr 229)
  6. Friedberg JW, Huang J, Dillon H, et al. Initial therpeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). Proc Am Soc Clin Oncol. 2006;24:428s;(abstr 7527)
  7. Balfour JA, Goa KL. Bendamustine. Drugs. 2001;61:631–638
  8. Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs. 1996;7:415–421
  9. Schwanen C, Hecker T, Hubinger G, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia. 2002;16:2096–2105
  10. Leoni LM, Niemeyer C, Bendall H, et al. SDX-105 (Treanda), active in non-Hodgkin’s lymphoma cells, induces the mitotic catastrophe death pathway. Blood. 2004;104:232b;(abstr 4593)
  11. Leoni LM, Bailey B, Reifert J, et al. SDX-105 (Bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action. Blood. 2003;102:640a;(abstr 2363)
  12. Leoni LM, Bailey B, Niemeyer C, et al. In vitro and ex vivo activity of SCD-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res. 2004;45:278;(abstr 1215)
  13. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomas. Anticancer Drugs. 2001;12:725–729
  14. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
  15. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732
  16. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986–1992
  17. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica. 2002;87:33–43
  18. Czuczman MS. Immunochemotherapy in indolent non-Hodgkin’s lymphoma. Semin Oncol. 2002;29:11–17
  19. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–3071
  20. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—A randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132:205–212
  21. von Minckwitz G, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): A phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs. 2005;16:871–877
  22. Brockmann B. [Therapy of the recurrence of malignant lymphoma]. Z Arztl Fortbild (Jena). 1992;86:843–846
  23. Kahl C, Herold M, Hoffkes HG, et al. Bendamustine, methotrexate, mitoxantrone, and prednisolone (BMMP) for the treatment of relapsed or refractory high-grade non-Hodgkin’s lymphoma. Onkologie. 1997;20:406–408
  24. Heck HK, Preiss JH, Schmidt P. Bendamustine (B) and mitoxantron (MITX) in the treatment of low-grade non-Hodgkin-lymphoma (NHL). J Cancer Res Clin Oncol. 1998;124(suppl):R147
  25. Konig U, Junghanss C, Decker S, et al. Response of refractory and relapsed low grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustinehydrochloride containing regimen. Ann Oncol. 1999;10:132;(suppl 3, abstr 479)
  26. Bremer K. Bendamustin: Effective salvage chemotherapy in pretreated low grade nonpHodgkin’s lymphomas (L.Gr.NHL). Ann Oncol. 1999;10(suppl):127
  27. Herold M, Schulze A, Mantovani L, et al. BOP versus COP in advanced low grade non-Hodgkin’s lymphomas—Results of a randomized multicenter study. Blood. 1999;94:262b;(abstr 4382)
  28. Ruffert K. Therapy of low grade non-Hodgkin’s lymphoma (NHL) with bendamustine and oral etoposide. Ann Oncol. 1999;10:125;(suppl 3, abstr 452)
  29. Kath R, Blumenstengel K, Fricke HJ, et al. [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]. Dtsch Med Wochenschr. 2001;126:198–202
  30. Kirchner HH, Gaede B, Steinhauer EU, et al. Chemoimmunotherapy with fludarabine, bendamustine and rituximab for relapsed low grade malignant non-Hodgkin’s lymphoma. Blood. 2001;98:135a;(abstr 568)

PII: S0037-1963(07)00094-7

doi: 10.1053/j.seminhematol.2007.06.003

Seminars in Hematology
Volume 44 , Pages S22-S26 , July 2007

Article Tools

* Image Usage & Resolution